搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
22 小时
on MSN
Dyne, Avidity initiated at outperform by RBC on DM1 drugs
RBC Capital has initiated coverage of Dyne Therapeutics (DYN) and Avidity Biosciences (RNA) with outperform ratings, citing ...
FierceBiotech
1 天
Sarepta pays $500M cash for rights to 'multiple potential blockbusters' from Arrowhead
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
7 小时
Avidity Biosciences: Advancing Clinical Programs with Strategic Focus and Growth Potential
In a report released on November 24, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Avidity Biosciences (RNA – Research ...
Investor's Business Daily on MSN
18 小时
Arrowhead, Sarepta Skyrocket After Duo Inks A Whopping $11.38 Billion Deal
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...
Fintel on MSN
1 天
RBC Capital Initiates Coverage of Avidity Biosciences (RNA) with Outperform Recommendation
Fintel reports that on November 26, 2024, RBC Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a ...
Cochrane
9 天
Medicines that increase alertness (psychostimulants) for excessive daytime sleepiness ...
Myotonic dystrophy is an inherited muscular dystrophy causing muscle weakness and wasting. Excessive daytime sleepiness (hypersomnia) is a frequent complaint of people with myotonic dystrophy and is ...
FierceBiotech
6 天
Novartis, assessing peers’ muscular dystrophy failures, pens $1.1B deal for gene therapy ...
Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire ...
MM&M
5 天
Novartis ups sales guidance, purchases Kate Therapeutics for up to $1.1B
Shareholders of Kate Therapeutics are entitled to receive up to $1.1 billion from the upfront payments and additional ...
BioPharma Dive
5 天
Novartis wagers more than $1B on gene therapies for the nervous system
In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...
BioSpace
6 天
Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030
Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈